Halda Therapeutics is a private company building in biotechnology. The latest valuation stands at $250M. The stock is not listed on any public market.
One company valuation: $250M.
Access IndustriesLEAD
Canaan PartnersLEAD
Khosla Ventures
DCVCAccess IndustriesCanaan PartnersHalda Therapeutics develops oral small-molecule cancer treatments using a technology it calls RIPTAC, short for Regulated Induced Proximity TArgeting Chimera, which pairs a cancer-specific protein with a protein the cell needs to survive so that binding the two kills the cancer cell while sparing healthy ones. Its lead drug, HLD-0915, a once-daily pill for advanced prostate cancer, is in an open-label Phase 1/2 study and showed early anti-tumor activity in its first 40 patients.
The company is based in New Haven, Connecticut, and spun out of Yale University research by professor Craig Crews, who also founded Arvinas. Halda emerged from stealth in 2023, and in November 2025 Johnson & Johnson agreed to acquire it for $3.05 billion in cash.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Halda Therapeutics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Halda Therapeutics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Halda Therapeutics included.
Lead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Halda Therapeutics is a private company; its shares do not trade on a public exchange.
The last valuation is $250M.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
